Company intelligence / Profile preview
Melius Pharma AB
Lund, Skåne County, Swedenmeliuspharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Melius Pharma’s lead candidate, ME‑015 (Suplatast Tosilate), is an oral small molecule with over 25 years of real-world safety data. It is being evaluated in a Phase 2 proof-of-concept study for chronic cough associated with idiopathic pulmonary fibrosis. The compound has shown efficacy and safety benefits across several exploratory studies targeting different types of chronic cough. Topline data from the ongoing Phase 2 trial are expected by early 2025
- Therapeutic areas
- Pulmonology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Melius Pharma AB.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Melius Pharma AB.